Seung Ha Lee1, Sang Joon Lee1, Yong Il Shin2, Hyung Bin Lim3, Jung Yeul Kim3, Yong Seop Han4, Ki Yup Nam5. 1. Department of Ophthalmology, College of Medicine, Kosin University, Busan, South Korea. 2. Rhee's Eye Hospital, Daejeon, South Korea. 3. Department of Ophthalmology, College of Medicine, Chungnam National University, Daejeon, South Korea. 4. Department of Ophthalmology, College of Medicine, Gyeongsang National University, Jinju, South Korea. 5. Department of Ophthalmology, Chungnam National University Sejong Hospital, Sejong, South Korea. oksnam1231@daum.net.
Abstract
PURPOSE: To compare visual improvements between initial intravitreal t-PA with gas injection before anti-vascular endothelial growth factor (VEGF) and anti-VEGF injection monotherapy for submacular haemorrhage (SMH) associated with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed medical records of naive patients treated with intravitreal t-PA with gas injection before anti-VEGF (Group 1) or only with intravitreal anti-VEGF injection (Group 2) for SMH [disc area (DA) ≥ 2] associated with AMD from two institutions. Both groups received 3 monthly loads of anti-VEGF injections followed by injections as needed for AMD treatment. Changes in best-corrected visual acuity (BCVA, logMAR) between the initial visit and after 6 months of treatment were compared between two groups. RESULTS: A total of 82 patients were enroled. Of these, 32 patients and 50 patients were grouped in Groups 1 and 2, respectively. The mean change in BCVA over 6 months for Group 1 was -0.52 ± 0.88, which was significantly larger (p = 0.044) than the mean change for Group 2 (-0.15 ± 0.58). We compared visual improvements between the two groups based on the following SMH size categories: ≤5, >5, and ≤15, and >15 DA. When the SMH size was ≤5, or >5 and ≤15 DA, the mean change in BCVA was larger for Group 1 than for Group 2, but this difference was not significant. When SMH size was >15 DA, Group 1 patients exhibited a mean visual improvement of -0.79 ± 0.80, which was significantly greater (p = 0.029) than that of Group 2 (-0.06 ± 0.67). CONCLUSIONS: Patients that were primarily treated for SMH associated with AMD using t-PA and gas injection (followed by anti-VEGF injection) exhibited better visual improvement than those treated with anti-VEGF monotherapy, especially in patients exhibiting larger SMH sizes (>15 DA) at the initial visit.
PURPOSE: To compare visual improvements between initial intravitreal t-PA with gas injection before anti-vascular endothelial growth factor (VEGF) and anti-VEGF injection monotherapy for submacular haemorrhage (SMH) associated with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed medical records of naive patients treated with intravitreal t-PA with gas injection before anti-VEGF (Group 1) or only with intravitreal anti-VEGF injection (Group 2) for SMH [disc area (DA) ≥ 2] associated with AMD from two institutions. Both groups received 3 monthly loads of anti-VEGF injections followed by injections as needed for AMD treatment. Changes in best-corrected visual acuity (BCVA, logMAR) between the initial visit and after 6 months of treatment were compared between two groups. RESULTS: A total of 82 patients were enroled. Of these, 32 patients and 50 patients were grouped in Groups 1 and 2, respectively. The mean change in BCVA over 6 months for Group 1 was -0.52 ± 0.88, which was significantly larger (p = 0.044) than the mean change for Group 2 (-0.15 ± 0.58). We compared visual improvements between the two groups based on the following SMH size categories: ≤5, >5, and ≤15, and >15 DA. When the SMH size was ≤5, or >5 and ≤15 DA, the mean change in BCVA was larger for Group 1 than for Group 2, but this difference was not significant. When SMH size was >15 DA, Group 1 patients exhibited a mean visual improvement of -0.79 ± 0.80, which was significantly greater (p = 0.029) than that of Group 2 (-0.06 ± 0.67). CONCLUSIONS: Patients that were primarily treated for SMH associated with AMD using t-PA and gas injection (followed by anti-VEGF injection) exhibited better visual improvement than those treated with anti-VEGF monotherapy, especially in patients exhibiting larger SMH sizes (>15 DA) at the initial visit.
Authors: Margaret A Chang; Diana V Do; Susan B Bressler; Sandra D Cassard; Emily W Gower; Neil M Bressler Journal: Retina Date: 2010-09 Impact factor: 4.256
Authors: A S Hassan; M W Johnson; T E Schneiderman; C D Regillo; P E Tornambe; L S Poliner; B A Blodi; S G Elner Journal: Ophthalmology Date: 1999-10 Impact factor: 12.079
Authors: Eva Stifter; Stephan Michels; Franz Prager; Michael Georgopoulos; Kaija Polak; Cornelia Hirn; Ursula Schmidt-Erfurth Journal: Am J Ophthalmol Date: 2007-10-04 Impact factor: 5.258
Authors: Gary Shienbaum; Carlos Alexandre A Garcia Filho; Harry W Flynn; Renata Portella Nunes; William E Smiddy; Philip J Rosenfeld Journal: Am J Ophthalmol Date: 2013-03-07 Impact factor: 5.258